Bayer (FRA:BAYN) Given a €81.00 Price Target by Independent Research Analysts

Share on StockTwits

Bayer (FRA:BAYN) has been given a €81.00 ($94.19) target price by equities researchers at Independent Research in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Independent Research’s target price indicates a potential upside of 6.96% from the company’s previous close.

Several other equities research analysts have also weighed in on BAYN. Kepler Capital Markets set a €73.00 ($84.88) target price on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, January 9th. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday, November 18th. Warburg Research set a €61.00 ($70.93) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, November 19th. Eight research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of €81.12 ($94.32).

Shares of BAYN opened at €75.73 ($88.06) on Tuesday. The company has a 50-day simple moving average of €72.24 and a 200-day simple moving average of €66.52. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hasbro, Inc.  Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Hasbro, Inc. Expected to Earn Q1 2020 Earnings of $0.01 Per Share
Halozyme Therapeutics, Inc.  to Post Q1 2020 Earnings of  Per Share, Piper Sandler Forecasts
Halozyme Therapeutics, Inc. to Post Q1 2020 Earnings of Per Share, Piper Sandler Forecasts
Q1 2020 EPS Estimates for Helios Technologies  Boosted by William Blair
Q1 2020 EPS Estimates for Helios Technologies Boosted by William Blair
Aergo Price Down 15.4% This Week
Aergo Price Down 15.4% This Week
Skychain  Market Capitalization Achieves $662,118.00
Skychain Market Capitalization Achieves $662,118.00
EveriToken  Trading Down 27.4% Over Last Week
EveriToken Trading Down 27.4% Over Last Week


 
© 2006-2020 Zolmax.